For older patients with cancer and type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with lower all-cause mortality than dipeptidyl peptidase-4 inhibitor ...

DALLAS — Results presented at the American Association of Hip and Knee Surgeons Annual Meeting showed 14 days may be the optimal cutoff time for glucagon-like peptide-1 receptor agonists prior ...

As a result, the mechanisms underlying the impact of glucagon-like peptide-1 medications on the kidneys are unknown. Clinical trials and animal research support GLP-1 medication usage to treat ...

Glucagon-like peptide-1 (GLP-1) receptor agonists -- your patients are on them, and perhaps you are too (or at least have thought about it). In 2023, more than 500 million people worldwide were ...

About The Study: In this cohort study, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) among patients with diabetes was associated with a 2-fold higher risk of incident ...

With glucagon-like peptide 1 (GLP-1) agonists now close to inducing weight loss at levels only seen before through surgical intervention, obesity specialists say patients on these drugs are ...

GLP-1 medications, or glucagon-like peptide-1 receptor agonists, treat type 2 diabetes and, in some cases, obesity. They work by mimicking the action of the hormone GLP-1, which helps regulate ...

They evaluated in vitro using reversed-phase ultraperformance-liquid chromatography (UPLC) and bioluminescence resonance energy transfer (BRET) assays. They also created conjugates containing ...

DALLAS — Glucagon-like peptide-1 receptor agonists may reduce complications after total knee arthroplasty in patients with obesity but who are not diabetic, according to presented results ...